CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
COMPUGEN LTD
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 2, 2026
$1.97+0.01 (+0.51%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 5.2
- Dividend yield
- –
COMPUGEN LTD revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Compugen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.